TNFRSF17 and plasma cell myeloma: Several clinical trials are currently underway to evaluate BCMA-targeted CAR-NK cells for the treatment of multiple myeloma, such as NCT05652530, NCT05008536, NCT03940833, NCT06045091, and NCT05182073 [64, 65] (Table 1).